At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
PIPE-505 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Unilateral Intratympanic PIPE-505 in Subjects With Sensorineural Hearing Loss Associated With Speech-in-Noise Impairment
In Brief
A Phase 2 clinical trial evaluating PIPE-505 and Placebo for Sensorineural Hearing Loss. Completed, enrolled 28 participants across 8 sites.
Detailed Summary
This is a randomized, double-blind study of PIPE-505, or placebo, in subjects with hearing loss associated with speech-in-noise impairment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSensorineural Hearing Loss
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartOct 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedJul 8, 2020
Enrollment StartOct 15, 2020
Primary CompletionJun 17, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.0 years ago
Interventions
PIPE-505drug
Intratympanic injection
Placebodrug
Intratympanic injection